In this context, we use a novel MNK/VEGFR2 dual inhibitor named JDB153 and provide available data to demonstrate its antitumor effect in combination with chemotherapy or immunotherapy, with the aim to aid feasible optimization for NSCLC treatment. This evidence concerns the gene KDR and non-small cell lung carcinoma.